What does a fecal calprotectin level greater than 200 µg/g indicate and how should it be evaluated and managed?

Fecal Calprotectin >200 µg/g: Evaluation and Management

A fecal calprotectin level greater than 200 µg/g indicates active intestinal inflammation and requires endoscopic assessment to determine the extent and severity of disease before making treatment decisions. 1

What This Level Means

A calprotectin >200 µg/g falls well above the threshold of 150 µg/g that the 2023 AGA guidelines use to define elevated biomarkers in inflammatory bowel disease (IBD). This level strongly suggests active inflammation, with approximately 4.8 times higher risk of disease relapse compared to patients with normal calprotectin 1. However, the critical point is that elevated calprotectin alone should not trigger empiric treatment changes—you need endoscopic confirmation.

Clinical Context Determines Next Steps

If the Patient is Asymptomatic (in Clinical Remission)

Proceed directly to endoscopic evaluation rather than empirically escalating therapy 1. Here's why:

• Even with calprotectin >200 µg/g, there's a significant false-positive rate (approximately 20-26%) where patients may not actually have endoscopically active disease 1
• The 2023 AGA guidelines explicitly recommend against empiric treatment adjustment based solely on elevated biomarkers in asymptomatic patients 1
• Exception: If the patient recently had endoscopy confirming remission (within 3 years) and biomarkers just became elevated, consider repeating the calprotectin in 3-6 months before proceeding to endoscopy 1

If the Patient Has Moderate-to-Severe Symptoms

For patients with ulcerative colitis presenting with frequent rectal bleeding and significantly increased stool frequency:

• You can proceed with treatment escalation without endoscopy 2
• At this calprotectin level with severe symptoms, the positive predictive value for moderate-to-severe endoscopic inflammation is high enough to justify treatment changes 2
• Endoscopy can be reserved for patients who prefer confirmation before starting or switching immunosuppressive therapies 2

For patients with Crohn's disease and moderate-to-severe symptoms:

• The evidence is less robust, but similar principles apply
• Consider radiologic assessment (MR enterography or CT enterography) for small bowel disease 1

If the Patient Has Mild Symptoms

Always perform endoscopy before treatment escalation 2. The specificity of calprotectin drops significantly in patients with mild symptoms:

• Approximately 15-22% false-positive rate even at levels >200 µg/g 2
• Mild symptoms could represent functional overlap rather than true inflammation
• Exception: If the patient just completed treatment adjustment for a recent flare and has mild residual symptoms, elevated calprotectin can guide further dose optimization without repeat endoscopy 2

Disease-Specific Considerations

Ulcerative Colitis

• Calprotectin >200 µg/g correlates well with endoscopic activity 3
• A cutoff of 250 µg/g provides 73% specificity for moderate-to-severe inflammation 2
• Higher levels (>800 µg/g) can differentiate active from inactive disease with greater confidence 3

Crohn's Disease

• Calprotectin at 250 ± 50 µg/g cutoff shows 76% sensitivity and 74% specificity for endoscopically active disease 1
• Consider that small bowel inflammation may not elevate calprotectin as reliably as colonic disease
• Radiologic assessment may be more appropriate for predominantly small bowel involvement 1

Common Pitfalls to Avoid

1. Don't empirically escalate therapy in asymptomatic patients with elevated calprotectin—the false-positive rate is too high 1

2. Don't assume normal calprotectin rules out inflammation in symptomatic patients—sensitivity drops in certain clinical scenarios, particularly with mild symptoms 2

3. Don't ignore recent surgical history—esophagogastric surgery can elevate calprotectin independent of IBD activity 4

4. Don't forget age-related considerations—while calprotectin remains sensitive in older adults (≥50 years), the positive predictive value drops significantly due to higher rates of other pathology 5

5. Don't use a single elevated value to make major decisions—if clinical context is unclear, repeat measurement in 3-6 months 1

Practical Algorithm

Step 1: Assess symptom severity

• No symptoms → Endoscopy (unless recent endoscopy within 3 years, then consider repeat calprotectin in 3-6 months)
• Mild symptoms → Endoscopy before treatment change
• Moderate-to-severe symptoms → Can treat empirically (especially UC), but endoscopy preferred if patient desires confirmation

Step 2: If endoscopy is delayed or declined

• Repeat calprotectin in 3-6 months
• If persistently elevated or rising, endoscopy becomes mandatory
• If normalizing, continue current therapy with close monitoring

Step 3: After endoscopy confirms inflammation

• Optimize or switch therapy based on endoscopic severity
• Use calprotectin for monitoring response (target <150 µg/g for remission) 1, 6